Journal
BLOOD
Volume 124, Issue 7, Pages 1062-1069Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-05-578435
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC
- Milan, Italy)
- Special Program Molecular Clinical Oncology 5x1000 [1005]
- Italian Ministry of Health [GR-2010-2312855]
- Fondo per Gli Investimenti della Ricerca di Base (FIRB) [F11J11000250001]
- Instituto de Salud Carlos III, Spanish Ministry of Health [RD012/0036/0004]
Ask authors/readers for more resources
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) carried an MPL (W515) mutation, and 53 (8.6%) had nonmutated JAK2, CALR, and MPL (so-called triple-negative PMF). Patients with CALR mutation had a lower risk of developing anemia, thrombocytopenia, and marked leukocytosis compared with other subtypes. They also had a lower risk of thrombosis compared with patients carrying JAK2 (V617F). At the opposite, triple-negative patients had higher incidence of leukemic transformation compared with either CALR-mutant or JAK2-mutant patients. Median overall survival was 17.7 years in CALR-mutant, 9.2 years in JAK2-mutant, 9.1 years in MPL-mutant, and 3.2 years in triple-negative patients. In multivariate analysis corrected for age, CALR-mutant patients had better overall survival than either JAK2-mutant or triple-negative patients. The impact of genetic lesions on survival was independent of current prognostic scoring systems. These observations indicate that driver mutations define distinct disease entities within PMF. Accounting for them is not only relevant to clinical decision-making, but should also be considered in designing clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available